Ariceum Therapeutics

Founded 2021
Employees 15+
Primary contact
Robert-Roessle Strasse 10
13125 Berlin
Germany
+49 30 9489 3360
Diseases & Conditions
Sections
Ariceum Therapeutics is a clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of "Marie Curie" whose discovery of radium and polonium have been huge contributions to finding treatments for cancer. Ariceum's lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan ("satoreotide") is an antagonist of the somatostatin type 2 (SST2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC), all of which have few treatment options and poor prognosis. Satoreotide is being developed as a "theranostic" pair for the combined diagnosis and targeted radionuclide treatment of these tumors.
Founded 2021
Employees 15+
Primary contact
Robert-Roessle Strasse 10
13125 Berlin
Germany
+49 30 9489 3360
Diseases & Conditions
Sections

Funding πŸ’°

Total €47.8M
Last round πŸ”— €22.75M
Series A extension
April 18, 2023.
Select investors EQT Life Sciences, HealthCap, Andera Partners, Earlybird Venture Capital, Pureos Bioventures

Key people πŸ§‘β€πŸ€β€πŸ§‘

Highlights ⭐

  • A global company: Ariceum is headquartered in Berlin, with operations in Germany, Australia and Switzerland and activities currently across Europe, North America and Australia.
  • Novel approach: Ariceum's novel targeting molecules have the advantage of being both diagnostic and therapeutic. The same drug conjugate could be used for both diagnostic imaging and therapeutic use by switching the radioisotope. Direct visualization of drug conjugate uptake by tumors with imaging allows for proper patient selection to receive the therapeutic radioisotope. It also will ensure that what you see is what you eliminate. πŸ”—
  • Acquired one company: On June 1st, 2023 - Ariceum announced the acquisition of Theragnostics Ltd., a UK-based private biopharmaceutical company engaged in the development of radio-labeled PARP inhibitors for the diagnosis and treatment of tumors. The acquisition provides Ariceum with an expanded portfolio of therapeutic and diagnostic assets in late preclinical and early clinical development. It also comprises NEPHROSCAN, a diagnostic product in partnership with GE Healthcare which is approved by the US FDA and affords Ariceum expanded operations in the US. πŸ”—

Quotes πŸ’¬

At Andera we have been following the radiopharmaceuticals space for some time, looking for an opportunity to support a compelling project. As a result, we are now very happy to be able to back the talented and experienced team of Ariceum with a first clinical project centered around a meaningful disease application in Small Cell Lung Cancer. It is great to support the company in its bold ambition to build a pipeline of radiopharma projects through deals and partnerships. We are also joining an already powerful board of experts and strong European VCs. Altogether, we believe these are solid grounds to build a leading biotech company in the radiopharmaceuticals field.
Olivier Litzka, PhD, Partner of Andera Partners πŸ”—
We are delighted to support Ariceum as it advances its proprietary clinical programs to address aggressive cancers with a poor prognosis. Earlybird is especially excited about Ariceum's ability to stratify patients for treatment via its theranostics approach. This will provide the best possible patient outcomes and attractive health economics. I look forward to working with Ariceum's experienced management team and strong investor base as it enters its next development stage.
Christoph Massner, PhD, Principal of Earlybird Venture Capital πŸ”—
Last update: June 4, 2023